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Abstract: Despite advances in diagnosis and management, cardiovascular diseases (CVDs) remain 22 
the leading cause of death in the US. Atherosclerosis is the most common form of CVD and the 23 
vulnerability of atherosclerotic plaques to rupture is a primary determinant for risk of catastrophic 24 
ischemic events. Current imaging of atherosclerotic disease focuses on assessing plaque size and 25 
the degree of luminal stenosis, which are not good predictors of plaque stability. Functional 26 
methods to identify biomarkers of inflammation in plaques could facilitate assessment of plaque 27 
instability to allow early intervention.  In this study, we validate the use of a purpose-built, 28 
magnetic resonance imaging (MRI)-compatible positron emission tomography (PET) insert for 29 
multimodal, molecular imaging of vulnerable plaques in mice. We illustrate the application of PET 30 
to screen for inflamed regions to guide the application of MRI. Molecular MRI visualizes regions 31 
of vascular inflammation and is coupled with anatomical MRI to generate detailed maps of the 32 
inflammatory marker within the context of an individual vessel. As a testbed for this imaging 33 
methodology, we developed a multimodal, iron oxide nanoparticle (NP) targeting vascular cell 34 
adhesion molecule-1 (VCAM-1) for simultaneous PET/MRI of vascular inflammation performed 35 
on a mouse carotid ligation model. In vitro cell studies confirmed that the NPs are not cytotoxic to 36 
liver cells. In vivo simultaneous PET/MRI imaging identified regions of inflammation. 37 
Three-dimensional rendering of the MRI data facilitated high-resolution visualization of patterns 38 
of inflammation along the injured vessel. Histology validated the co-localization of the NPs with 39 
VCAM-1 expression at sites of induced inflammation. The results of this work validate the utility 40 
of the simultaneous PET/MR insert as a research tool for small animals and lays groundwork to 41 
further advance the potential clinical utility of integrated imaging systems. 42 
Keywords: Multimodality imaging; MRI/PET; dual-mode imaging; nanoparticle; atherosclerosis; 43 
vulnerable plaque; cardiovascular imaging; vessel wall; VCAM. 44 
 45 
1. Introduction 46 
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Cardiovascular disease is the leading cause of death for both males and females in the United 47 
States.[1] In particular, atherosclerosis is responsible for catastrophic manifestations of heart disease 48 
such as myocardial infarction and stroke.[2] Recent understanding of the pathophysiology of 49 
plaque formation has identified chronic inflammation as a hallmark of plaque development; 50 
localized inflammatory response can lead to the development of “vulnerable” plaques that are 51 
prone to rupture and cause downstream vascular occlusion.[3] Imaging can play a role in 52 
identifying patients with vascular lesions susceptible to acute cardiovascular events, who may be 53 
amenable to treatment with anti-inflammatories or interventional procedures. Recent literature has 54 
shown that plaque lesion composition, particularly the presence of inflammatory markers and 55 
immune cells, as opposed to the degree of vessel stenosis, is a better predictor of patient mortality 56 
and morbidity; and assessment of plaque inflammation is an excellent target for noninvasive 57 
imaging.[4] However, current clinical imaging techniques seldom provide specific information 58 
about inflammation. 59 
Current clinical imaging techniques such as coronary angiography, vascular ultrasound and 60 
computed tomography focus on identifying stenotic disease and can miss vulnerable plaques that 61 
do not cause significant structural stenosis.[5] Anatomical features identified by coronary computed 62 
tomography (CT) and magnetic resonance imaging (MRI) that could be used to classify plaques, 63 
have not been fully validated for prediction of vulnerability.[6] Targeted molecular imaging has 64 
potential for greater predictive value. For example, imaging of plaque inflammation has been 65 
actively pursued using 18F-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) 66 
and has shown promise for identifying inflammation, generally in large vessels such as the carotid 67 
and aorta.[7-10] However, it is challenging to accurately assess inflammatory burden in small 68 
vessels with the limited resolution of PET.[11] Moreover, FDG is a non-specific marker of 69 
inflammation that measures only glucose uptake, which presents challenges for coronary artery 70 
imaging against the high metabolic background of the myocardium.[12] Enthusiasm for the clinical 71 
use of 18FDG to identify plaques has diminished over recent years with new tracers such as 18NaF 72 
receiving greater attention; but specific imaging of plaque inflammation is still not available.[13] 73 
New, targeted imaging strategies that can identify inflamed plaques in smaller vessels, such as the 74 
coronary arteries, with higher specificity are needed.  75 
We have previously shown that multimodal agents combining positron emission tomography 76 
(PET) and magnetic resonance imaging (MRI) can detect macrophage density in plaques, using the 77 
quantitative ability of PET for high sensitivity mapping of the cells, and MRI for high spatial 78 
resolution molecular imaging and soft tissue mapping.[14] Our previous work utilized separate 79 
scanners to visualize the synergistic PET and MRI information. This required laborious spatial 80 
co-registration (prone to misalignment since they are acquired sequentially), more involved 81 
handling of subjects with longer sedation, and time delay due to the need for transport between 82 
PET and MR scanners. The latter factor also prevents temporal co-registration of the PET and MRI 83 
signals. Not only does this hinder throughput of preclinical research pursuits, but also may limit 84 
the translatability of such agents to the clinic.  The use of hybrid modality instruments for 85 
simultaneous signal acquisition is, thus, of increasing interest in the imaging field and clinical 86 
hybrid instruments are now available; but the ideal cardiovascular applications for these hybrid 87 
systems are still under investigation.[15] 88 
In this proof of concept study, we demonstrate the utility of simultaneous PET and MRI to 89 
facilitate PET-guided MRI mapping of localized inflammation in small vessels using an integrated 90 
small animal simultaneous PET/MRI imaging system developed at UC Davis and a dual-mode 91 
contrast agent targeted to Vascular Cell Adhesion Molecule 1 (VCAM-1).[16, 17] Vascular Cell 92 
Adhesion Molecule VCAM -1 has received attention for imaging of atherosclerotic plaques due to 93 
its overexpression in the pathogenesis of vulnerable plaques. It has been studied for single modality 94 
imaging by MRI[18], SPECT[19, 20], and ultrasound[21]. Each of these modalities holds inherent 95 
limitations for targeted vascular imaging.  MRI and ultrasound can provide excellent local, spatial 96 
information at the lesion site, but are ill-suited to whole-body screening. PET is superior for 97 
screening, but lacks the spatial resolution to identify individual vessels. While computed 98 
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tomography (CT), can provide structural information, but does not provide physiological 99 
information at the lesion site. MRI/PET has the potential to overcome these difficulties by 100 
combining the screening power of PET with the resolution power of MRI, enabling concurrent 101 
assessment of cardiovascular structural and physiological abnormalities.[22] We evaluated the 102 
ability of the integrated PET/MRI instrument to visualize sites of localized inflammation induced by 103 
carotid injury in a mouse model; the mouse carotid is of similar size to human coronary arteries. 104 
PET provided an overview of inflamed regions, which was used to focus MRI interrogation and 105 
obtain higher resolution, 3-dimensional details of VCAM-1 expression in single vessels.  106 
2. Results and Discussion 107 
Nanoparticles (NP) were successfully synthesized (outlined in Figure 1 and described in 108 
Methods). 109 
Figure 1. Synthesis of VDIO-DOTA nanoparticles. (a) Synthesis of dextran coated iron oxide 110 
nanoparticle (b) Conjugation of DOTA and VCAM-1 targeting peptides to nanoparticles.  111 
 112 
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2.1 Characterization of VDIO-DOTA and DIO (control) 113 
DIO (dextran-coated iron oxide) was synthesized as a matched control to the prepared 114 
VDIO-DOTA (DOTA= 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid; VDIO= 115 
VCAM-conjugated DIO;). The physical properties of VDIO-DOTA and its precursor DIO are 116 
summarized in Figure 2a. Following the syntheses described, the DIO and VDIO-DOTA iron oxide 117 
core sizes were measured to be 7.3 ± 2.9 nm by averaging 500 particle measurements from TEM 118 
images as shown in representative images in Figure 2b and 2c. Inset plots show that the 119 
hydrodynamic diameters of DIO and VDIO-DOTA were found to be 39.7 ± 15.0 nm and 48.1 ± 120 
19.5nm, respectively, using dynamic light scattering (DLS). The increased hydrodynamic diameter 121 
could be explained by the addition of peptide polymers on the VDIO surface holding the dextran 122 
polymers apart via steric hindrance. However, the core sizes remained the same.   123 
Figure 2. (a) Summary of nanoparticle properties. TEM images of (b) DIO (core size: 7.30 ± 2.92nm) 124 
(C) VDIO-DOTA (core size: 7.30 ± 2.92nm). Scale bars = 50 nm, insets are DLS data.  125 
Nanoparticles Core size (nm) Average 
hydrodynamic 
diameter (nm) 
Relaxivity (mM-1s-1) 
(1.4 T, 37°C) 
% 
Iron 
  r1 r2  
VDIO 7.30 ± 2.92 48.10 7.38 67.85 21 
DIO 7.30 ± 2.92  39.7 10.05 68.83 16 
 
(a) 
 
(b) 
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(c) 
The iron concentration (mg per unit mass) in DIO and VDIO-DOTA was measured by atomic 126 
absorption (AA) to be 0.161 and 0.037 mg Fe/mg of nanoparticles, respectively. The longitudinal (r1) 127 
relaxivity of VDIO-DOTA at 60 MHz (1.4 T, 37 °C, pH = 7) was 7.4 mM-1s-1 and transverse relaxivity 128 
(r2) was measured as 67.9 mM-1s-1. DIO had r1 and r2 values of 10.1 mM-1s-1 and 68.8 mM-1s-1, 129 
respectively. The r2 to r1 ratio for both reflects their suitability as T2-weighted MRI contrast 130 
agents.[17] VDIO-DOTA relaxivity and size remained stable after 1 year of dry storage at room 131 
temperature. 132 
2.2 Contrast Agent is Not Cytotoxic to Liver Cells in vitro 133 
Given that NPs are expected to clear through the liver, liver cells may be exposed to the 134 
highest off-target concentration of injected contrast agent. Thus, C12 – Resazurin viability assays 135 
were performed on HepG2 liver cells to evaluate any toxicity exhibited by VDIO-DOTA.[23] In this 136 
assay resazurin is reduced to resorufin in proliferating cells.[23] Cell survival was evaluated after 137 
incubation for 4, 24, and 48 hours with different concentrations of VDIO-DOTA, ranging from 0.04 138 
mM iron (red), 0.2 mM iron (blue), 1 mM iron (teal), 4 mM iron (pink) to 10 mM iron (khaki). With 139 
90% confidence interval by t-test there were no differences between the untreated control (0.0 mM 140 
iron, black) and cells treated at all concentrations of VDIO-DOTA tested from 0.04 mM iron up to 10 141 
mM iron. These results support that the nanoparticles are nontoxic to liver cells at relatively high 142 
concentrations. 143 
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 144 
Figure 3. The fractional survival of HepG2 after 4, 24 and 48 hours of incubation with VDIO 145 
solutions of varying concentrations. At each time point, fluorescent intensities reflecting survival 146 
fractions (y axis) were normalized against the signal from the untreated control group (black bar at 147 
each time point). 148 
2.3 VDIO-DOTA can to detect inflamed vessels in vivo  149 
MRI only studies were performed to determine appropriate dosing prior to PET/MRI studies. 150 
Representative MRI scans showing VDIO-DOTA uptake at the three injection concentrations are 151 
shown in Figure 4a (n = 4 mice per concentration). The leftmost column shows cross sections 152 
through the entire animal for, from top to bottom 6mg/ml, 30mg/ml and 60 mg/ml injection of 153 
nanoparticles. These are labeled with colored circles to indicate the injured vessel (yellow circle), 154 
uninjured contralateral vessel (red circle) and spinal cord (green circle). The co-registration 155 
standards are also visible to left and right of the animal. The regions outlined by the yellow boxes 156 
are presented in zoomed views on the matrix of images on the right, which show, from left to right, 157 
images from this region taken pre-injection, and images 4 and 24 hours after injection of contrast. 158 
For all concentrations, the inflamed vessel (yellow arrows) showed expected increased dephasing 159 
(seen as signal dropout) as the concentration of VDIO-DOTA injected is increased resulting in 160 
greater accumulation at the ligated site compared to the nonligated contralateral vessel (red 161 
arrows). This darkening in the inflamed arteries persists through the 24h timepoint for all 162 
concentrations, showing sustained retention of the particles at the site of inflammation. Robust 163 
signal for 6ml/ml suggested that even lower injection concentrations could be employed. The CR 164 
was calculated as a function of time after injection and dosage and shown in the accompanying 165 
graph in Figure 4b. Although the 60 mg Fe/kg dose showed the greatest signal decrease on the 166 
images, maximal CR was achieved with the 30 mg Fe/kg dosage at both 4h and 24h after injection of 167 
contrast. This highlights the need to achieve a balance between local accumulation of the NP, 168 
retention over time, and its systemic circulation for optimal visualization of the region of interest. 169 
Using these results as a guide, 30mg Fe/kg was used for the remainder of the studies. 170 
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(a) (b) 
Figure 4.(a) MRI-only study showing VDIO-DOTA uptake at different injection concentrations over 171 
24 hours. The yellow arrows point to the inflamed vessel, while the red arrows indicate the 172 
non-inflamed control vessel. There was signal decrease at the site of injury at all dosages; but the 173 
decrease was most prominent at the 30 and 60 mg Fe/kg. The regions of interest for Contrast Ratio 174 
(CR) calculation are shown by the circles. (Scale bar = 5 mm). (b) Contrast ratio as function of time 175 
and dose for MRI-only studies. Compared to baseline, the 6 mg Fe/kg dose level did not 176 
demonstrate significant local accumulation of NP at the site of inflammation. Both the 30 mg Fe/kg 177 
and 60 mg Fe/kg showed increased accumulation of NP at the site of inflammation; the 30 mg Fe/kg 178 
dose demonstrated the highest CR, likely due to the reduction of signal differentiation between the 179 
localized accumulation and systemic distribution of NP at the 60 mg Fe/kg dosage. Thus the 30 mg 180 
Fe/kg dose was used for subsequent studies. (Error bars denote the SEM). 181 
Following these MRI only studies, we evaluated VDIO-64Cu-DOTA nanoparticle accumulation 182 
in vivo by hybrid PET/MRI. Figure 5 shows image slices by MRI (top row), by PET (middle row) and 183 
the overlay (bottom row) from the same cross section in a representative mouse (n = 4 mice total). 184 
Prior to injection of VDIO-64Cu-DOTA, no MR or PET signal beyond background levels was seen 185 
within the animal. At 4 h post injection, both carotids demonstrated PET signal, which was higher 186 
in the injured vessel, suggestive of radiolabeled NP accumulation at the site of injury along with 187 
continued systemic circulation of unbound NP. Another focus of PET uptake within the field of 188 
view appear to correspond with a vein, supporting that systemic circulation of the NP remains at 189 
this time point, but which could represent another site of inflammation in the animal. In the slice 190 
shown, at 4 h there is a signal increase in the ligated vessel (yellow arrow) at a ratio of 1.19 191 
compared to the uninjured contralateral vessel; at the 24 h time point the ratio of the ligated site 192 
compared to the contralateral artery was 1.07; partial volume effects limits the accuracy of these 193 
measurement. We also calculated the MRI contrast ratio (CR; see equation in methods 4.6.3) from 194 
the concurrent MRI dataset. Note that CR also is a comparison against the contralateral control, 195 
thus taking into account contributions from signal in the blood. For this particular animal, the MRI 196 
CR was 1.41 at the 4 h time point and 0.62 by 24 h, indicating elevated NP accumulation at the 197 
ligated site at the 4 h timepoint with decreased MRI signal by 24 h, commensurate with the PET 198 
results. This slice was selected to illustrate the point that these trends are for this slice, in this 199 
particular animal and based on this slice only one may conclude there was no inflammation in this 200 
vessel. For a more accurate view of inflammation the entire affected volume should be considered, 201 
as well as the full set of experimental subjects. As shown later, mapping inflammation throughout 202 
the vessel provides a clearer picture of inflammatory burden. The MRI CRs for the entire PET/MRI 203 
cohort were 1.65 ± 0.26 at 4 h and 1.66 ± 0.39 at 24 hours respectively. In general, this is in agreement 204 
with the data for the MRI only cohort, which also demonstrated an increased MRI CR over the 24 h 205 
period (Figure 5b). Note that these results support that ligation does not prevent contrast agent 206 
5mm 2mm 
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access to the injured carotid—if this had been the case there would be less signal drop out due to 207 
reduced perfusion to the region.  208 
 209 
Figure 5. PET/MR imaging of dual-mode VDIO-DOTA accumulation in carotid artery of ApoE-/- 210 
mouse with vascular inflammation (atherosclerotic plaques) induced by ligation. MRI-only images 211 
preinjection (a), after 4h(b) and 24h(e) injection, PET/MRI co-registered images after 4h(c) and 24h(f) 212 
injection and PET-only images after 4h(d) and 24h(g) injection are shown. The image slices were 213 
from the same cross section of the mouse and showed spinal cord (grey oval area in the middle), left 214 
carotid (after ligation) artery (denoted by yellow arrow) and right carotid artery (denoted by red 215 
arrow). The color maps for the PET images were set such that the highest values (as indicated by 216 
red) reflected the highest signal within the animal image volume for the particular time point. The 217 
white circles are markers for MRI intensity standards. (Scale bar = 5 mm). 218 
The lower resolution of PET provides decreased accuracy in determining inflamed regions due 219 
to partial volume effects, and subtle inflammatory lesions may be missed. This is suggested by the 220 
fact that although analysis of the MRI data suggested there was accumulation of the NP at the 221 
ligated site, this was not reflected by the simultaneously acquired PET data. The ratios of the PET 222 
signal at the ligated artery compared to the control artery were 1.05 ± 0.04 at 4 hours and 0.82 ± 0.33 223 
at 24 hours. This highlights the need for high-resolution 3D renderings of the affected volume to 224 
better identify regions of high inflammatory activity and assess degree of instability. For improved 225 
volume visualization, we performed three-dimensional rendering of the MRI data as shown in 226 
a b e
c f
d g
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Figure 6. MRI rendering is able to define regional accumulations and concentration differences for 227 
VDIO-DOTA in the vessel wall, allowing us to better localize VCAM-1 expression to specific 228 
regions in the inflamed vessel. Figure 6a and b show rendering of the MRI only data from the 30 mg 229 
Fe/kg dose injection for a representative animal, with a slice from the anatomical MRI included for 230 
anatomical context; this is the same animal and slice view used for the cross section image shown in 231 
Figure 4. The color map (transfer function) for the image was set to define three major color zones 232 
representing low (red), medium (blue), and high (pink) NP uptake. Greater susceptibility from 233 
T2-weighting indicates regions of greater particle accumulation (more red). The volume renderings 234 
suggest that VCAM-1 expression, which is targeted by the NPS and indicative of activated 235 
endothelial cells and inflammation, is diffuse along the vasculature and that expression patterns 236 
vary across the vessel. In this particular animal there is a greater accumulation of contrast agent on 237 
one side of the vessel as seen in the 4 h still images in panel a. At 24h (panel b) the trend persists 238 
and one can observe accumulation on one side that is consistent with the 4-hour data.   239 
Figure 6. Three-dimensional rendering of MRI data (a – b). Medium dose study, MRI data (from 240 
Figure 3). (a) Still frames from video depicting a rotating view of the inflamed vessel 4 h after 241 
injection of contrast agent. (b) Similar data for the vessel at 24 h. A similar trend for higher 242 
accumulation of contrast agent on one side of the vessel is preserved at both time points. (c – d) 243 
PET/MRI study, MRI data (From Figure 4). (c) Still frames from video depicting a rotating view of 244 
the inflamed vessel 4 h after injection of contrast agent. (d) Similar data for the vessel at 24 h. A 245 
trend for a “hot spot” (red) accumulation of contrast agent at the same location is seen at both time 246 
points.  Transfer functions used for color assignments are displayed as color bars shown between 247 
the 4 and 24h data sets. 248 
 249 
Figures 6c and d display rendering of the MRI data for the animal shown in the PET/MRI 250 
images of Figure 5. Inflammation is even more heterogeneous in this animal and NP accumulates in 251 
patches throughout the vessel. A local “hot spot”, appears in the 4 h data (panel c) and persists but 252 
is decreased through the 24 h time point (panel d) commensurate with the PET and MRI CR results. 253 
At 24 h most of the hot spot lies below the plane of interrogation that was show in the slice in 254 
Figure 4; this may explain the lack of PET observed in the slice shown and also underscores the 255 
value of evaluating 3D data sets as volume renderings. The rendering provides insight into the 256 
heterogeneity of the NP accumulation, which is not readily apparent from slice by slice 257 
visualization of the MRI image set. This data correlates with the histological data, described in the 258 
next section, which showed inhomogeneous regional accumulations of the nanoparticles that 259 
overlap with regions showing high VCAM-1 expression. The morphology of the local plaque load 260 
can have prognostic implications.[24] Thus, this additional information from the high resolution 261 
MRI may provide vital information for clinical management. 262 
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The addition of a 3D visualization is very useful for interpreting these types of data sets where 263 
the disease is diffuse and lesions can span across multiple slices. One of the challenges for 3D 264 
rendering is the ability to create images and videos without the need for extensive manual 265 
segmentation, i.e. user delineation of pathology. The renderings shown here were created using 266 
software created at UC Davis that performs intensity-based segmentation by applying a 267 
user-defined color map to all voxels in the data set. This removes some degree of subjectivity from 268 
the assignment of pathological features. 269 
2.4 Iron co-localizes with VCAM-1 expression 270 
Mice were sacrificed after in vivo MRI only or PET/MRI study and organs of interest were 271 
collected for further analysis. For the MRI only studies, the tissues from mouse carotids were 272 
embedded into paraffin sections for histological study to examine iron accumulation (Figures 7a, c, 273 
e) and VCAM-1 expression (Figures 7 b, d, f) in the tissues. Prussian Blue staining was used to 274 
detect ferric ion (Fe3+) in the tissue. As shown in Figure 7a blue staining demonstrated that iron 275 
could be found in the intima in the inflamed carotid artery (arrow). Anti-VCAM-1 antibody 276 
staining was performed on an adjacent section (Figure 7b), which confirms the presence of VCAM-1 277 
in the same region, as indicated by dark brown stain of the intima on the left side of the vessel 278 
lumen (arrow). The dark blue iron staining co-localized in the regions of darkest brown VCAM-1 279 
staining, supporting that the nanoparticles were co-localized with VCAM-1 expression. There 280 
appears to be a thin layer of VCAM-1 staining on the rest of the lumen that does correlate with 281 
some iron staining. The faint brown stain over the entire intima represents nonspecific staining that 282 
is also found in the control vessel. Non-inflamed contralateral vessel showed no iron (Figure 7c) or 283 
dark brown VCAM staining (Figure 7d). 284 
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 285 
Figure 7. Iron colocalizes with VCAM-1 expression. (a). Prussian Blue staining hows iron on tissue 286 
cross section from inflamed mouse carotid artery. (b). Immunohistochemical staining shows 287 
VCAM-1 (brown) on a tissue slice adjacent to that shown in A. (c). Prussian Blue staining showed no 288 
iron in tissue cross section from normal mouse carotid artery and (d) no VCAM-1 staining on 289 
neighboring tissue slice. (e) Higher magnification view of Prussian Blue staining in  panel a at 10X, 290 
20X and 40X. (f) Higher magnification views of VCAM-1 staining in panel b. Dashed boxes indicate 291 
the area of interest with increasing magnification, moving left to right. Staining appears localized to 292 
the monolayer of endothelial cells lining the vessel.  293 
VCAM-1, triggered by inflammatory cytokines such as TNF-α, is expressed by endothelial cells 294 
as a prelude to the recruitment of macrophages into plaques. In our previous work to label 295 
macrophages in the injury model, animals were placed on fat diet for 2 weeks after ligation; the 296 
current studies were performed 8 days after ligation. At this earlier time point, plaque size and 297 
macrophage involvement are minimal as can be seen in the higher magnification histological 298 
images. Figure 7e shows iron staining at increasing magnifications from left to right and iron 299 
Figure 6
a b
c d
e
f
  
staining localized to cells of the intima, which is still generally a monolayer of endothelial cells. 300 
Figure 7f shows VCAM-1 staining at increasing magnifications from left to right, which shows 301 
VCAM-1 localized to the same monolayer. There was no intimal thickening, or obvious 302 
macrophage accumulation observed in the histological slices. The iron stain also appeared confined 303 
to a monolayer of "cobblestone-like” endothelial cells and there was no evidence of macrophages, 304 
which display surface ruffles and blebs. These results support that the NPs were binding to 305 
VCAM-1 expressed on endothelial cells.  306 
4. Conclusions 307 
In this study, we evaluated the use of a simultaneous hybrid PET/MRI system and multimodal 308 
nanoparticle contrast agent to visualize distribution of an early marker of inflammation. We found 309 
robust spatial-temporal co-localization of the PET and MRI signal, and identified regions of 310 
inflammation, which were confirmed by histological staining. PET, limited by its lower spatial 311 
resolution, could not specifically map inflammation in the vessels. PET also missed elevated 312 
contrast that was detected by MRI, likely due to signal averaging effects of diffuse inflammation in 313 
the tissues. But the sensitivity of PET allowed detection of inflammation in a larger volume map 314 
and served to guide MR imaging. Careful analysis of the MRI data, aided by 3D volume rendering, 315 
demonstrated a heterogeneous pattern of VCAM-1 expression extending beyond the site of vessel 316 
injury. The morphology of the local inflammation patterns can have prognostic implications.[24] 317 
This high-resolution mapping of early stage inflammation would not have been possible with MRI 318 
alone as lesions are difficult to detect in small vessels against anatomical background. Whole body 319 
MRI screening in humans would be even more challenging. Thus, the combination of PET and MRI 320 
provided complementary functions in this imaging application. 321 
Simultaneous PET/MRI imaging of the multimodal NP afforded a number of advantages over 322 
serial imaging including: 1) avoiding movement of the subject between scanner-, which allowed for 323 
facile spatial co-registration to do the lack of soft tissue movement experienced with scanning with 324 
separate instruments; 2) eliminating time delay between PET and MRI scans, which avoided 325 
complications with subject transport under anesthesia; 3) reduced exposure to personnel associated 326 
with handling and transporting the subject between instruments in different facilities. Given that 327 
many high-resolution MRI techniques are often time consuming and have a limited field of view, 328 
the availability of hybrid instrumentation can allow us to localize the ROI using PET without loss of 329 
spatial fidelity that would come with moving the subject to a separate scanner. This would be 330 
especially important in the clinical scenario whereby the site of injury may not be known a priori. 331 
The approach of using hybrid PET/MRI instrumentation along with multimodal imaging 332 
probes provides a powerful platform for both research and clinical pursuits. From a research 333 
perspective, hybrid imaging can provide direct information about the efficacy and distribution of 334 
multimodal molecular imaging agents, providing vital information to refine and improve the signal 335 
characteristics of these agents. From a clinical perspective, PET/MRI hybrid instruments are 336 
available now in a limited number of locations and their optimal applications are under 337 
investigation. Oncological applications have been some of the earliest imaging studies to 338 
demonstrate beneficial results from hybrid PET/MRI.[39, 40] For example, a study of PET/MRI for 339 
clinical prostate cancer imaging found that PET/MRI may demonstrate improved sensitivity to 340 
metastatic lesions compared to PET/CT.[41] Hope for improved diagnoses through hybrid PET/MRI 341 
is high for neurological applications, where the temporal alignment of hybrid instruments could be 342 
an advantage for examining brain processes in real-time.[16] 343 
Cardiovascular applications that could benefit from PET/MRI are still under investigation [22, 344 
42]; however, the simultaneous acquisition capability could offer advantages for imaging fast 345 
moving hearts and arteries. Most reports with PET/MRI have focused primarily on unimodal 346 
contrast agents such as 18FDG using MRI as an anatomic reference.[15, 43, 44] We demonstrate that 347 
PET-guided MRI using multimodal agents can facilitate high-resolution visualization of molecular 348 
targets, and establish utility for mapping a marker associated with inflammation. This can serve as 349 
a powerful research tool for drug validation by allowing monitoring of biomarker targets. Early 350 
  
diagnosis and patient stratification by PET/MRI could provide clinical benefit as drugs to 351 
ameliorate plaque vulnerability come available.  352 
In summary, we have demonstrated an approach to identify early inflammatory changes in 353 
vessel injury using a targeted multimodal probe coupled with hybrid PET/MRI imaging in vivo. 354 
Such approaches may be able to provide important insights into the pathophysiology and clinical 355 
management of vulnerable plaques. Furthermore, simultaneous PET/MRI allowed direct 356 
comparison of the PET and MRI signal, providing insights into the signal derived from the 357 
multimodal agent that can guide continued development of the instrument as well as the imaging 358 
agent. 359 
 360 
5. Materials and Methods  361 
5.1 Materials 362 
Materials were obtained from commercial suppliers and used directly, unless otherwise noted. 363 
Dextran (from leuconostoc, average mol. wt. 9,000–11,000) and ferric chloride hexahydrate 364 
(FeCl3·6H2O, Fw 270.29 g/mol) were purchased from Sigma-Aldrich. Ferrous chloride tetrahydrate 365 
(FeCl2·4H2O, Fw 198.81 g/mol) was from Fluka. Ammonium hydroxide (28–30%), sodium 366 
bicarbonate, and sodium hydroxide were from Fisher Scientific. p-SCN-Bn-DOTA was from 367 
Macrocyclics, Inc (Dallas, TX). N-succinimidyliodoacetate (SIA), purchased from Pierce (Rockford, 368 
IL). Spectra/por® dialysis membrane (mol. wt. cut-off 50,000) was acquired from Spectrum 369 
Laboratories, Inc. The VHPKQHR(MiniPEG1)C peptide was from Genscript (≥ 95% purity). Water 370 
was purified using a Millipore Milli-Q Synthesis purifier (18.0 MΩ cm, Barnstead).  371 
5.2 Nanoparticle synthesis and characterization 372 
5.2.1 Synthesis of dextran coated iron oxide (DIO) nanoparticles 373 
Dextran was reduced by published methods as summarized here and outlined in Figure 1.[25] 374 
Nanopure water (18.0 MW cm, Barnstead) was degassed with argon and used throughout the 375 
synthesis process. A mixture of dextran (molecular weight 10,000) and sodium borohydride (26 376 
equivalents) was stirred at room temperature for 12 hours. The solution was adjusted to pH=7, 377 
dialyzed against degassed nanopure water and lyophilized to form reduced dextran as a white 378 
solid. A mixture of reduced dextran and FeCl3·6H2O in a molar ratio of 1:27 (total polysaccharide: 379 
FeCl3·6H2O) was dissolved in deionized nanopure water. The solution was bubbled with argon and 380 
cooled to 4 °C in an ice-water bath. Fe2+ solution was freshly prepared by dissolving FeCl2·4H2O in 381 
degassed water (with a Fe3+:Fe2+ ratio in a range from 1.47 to 1.5) and stored on ice. The Fe2+ solution 382 
was added to Fe3+ mixture using a syringe followed by adding chilled (4 °C) NH4OH (NH4OH: Fe3+ = 383 
16:1) dropwise with vigorous stirring. The ice-water bath was removed and the mixture was heated 384 
to 85 °C and kept at 85 ± 5 °C for 2 hours (argon flow may stop 2–3 min after the temperature 385 
reaches 85 oC). After cooling to room temperature, the solution was dialyzed against deionized 386 
water in a dialysis bag with a molecular weight cut-off of 50,000 Da for 72 hours with 8-10 changes 387 
of water to remove reactants. The resulting product, DIO, was lyophilized and stored at 4 °C.[26] 388 
5.2.2 Cross-linking and amination of the DIO nanoparticles 389 
The DIO nanoparticles were cross-linked and aminated for the attachment of two ligands: 390 
DOTA (chelator of radioactive 64Cu) and the VCAM-1 targeting peptide (Figure 1). The 391 
cross-linking and amination were performed as previously reported with slight modifications.[27] 392 
DIO (2.0g), NaOH (4.02g) pellets and deionized water (40mL) were added to a 100mL 393 
round-bottomed flask and stirred for 30 min. Then epichlorohydrin was added to the mixture and 394 
the solution was stirred for 24h. The solution was dialyzed against deionized water with 8-10 395 
changes of deionized water and lyophilized to yield brown solid. The solid (2.0 g), together with 396 
ammonium hydroxide (250mL), was then transferred to a 500mL round-bottomed flask and stirred 397 
  
for 36h. Excess ammonium hydroxide was removed by dialyzing the solution against deionized 398 
water for 72h with 8-10 changes of deionized water. 399 
5.2.3 Conjugation of DOTA and VCAM-1 targeting peptide to the nanoparticle surface 400 
DOTA was conjugated to the aminated DIO surface based on a literature method. Briefly, 401 
p-SCN-Bn-DOTA (6.71mg), aminated nanoparticle (135mg) and 0.1 M sodium borate buffer 402 
solution (2mL) were added to a 10 ml round-bottomed flask (Figure 1b)[28]. Approximately five 403 
drops of sodium hydroxide aqueous solution (1N) was used to bring the solution pH to 8.5. The pH 404 
of the mixture was monitored during the reaction. The mixture was stirred for 24h, then dialyzed 405 
against deionized water for 72h with 8-10 changes of water in a dialysis bag with a molecular 406 
weight cut-off of 50,000 Da and then lyophilized to give a brown solid of DOTA conjugated 407 
aminated DIO (DIO-DOTA). The conjugation of DOTA to the aminated DIO was confirmed by 408 
Fourier Transform Infrared (IR) Spectroscopy. DIO-DOTA was then used for anti-VCAM-1 peptide 409 
attachment based on previous report[29], described here briefly.  410 
DIO-DOTA (22mg Fe in 1.5mL DMSO) was added to 0.5mL of 0.1M Na2HPO4 in water and 411 
0.5mL of 15mM SIA in DMSO in a 10mL round-bottomed flask. The mixture was stirred for 1h at 412 
room temperature followed by another addition of 0.5mL of 15mM SIA 413 
(N-succinimidyliodoacetate) in DMSO. Iodoacetyl-DIO was separated from iodoacetic acid using a 414 
Sephadex G-25 column equilibrated with 0.025M citrate buffer pH 6.5 at 4 °C. Then 6-7 mg of 415 
polymer-modified peptide (VHPKQHR(MiniPEG1)C) in 0.6mL of citrate buffer was added to 5mL 416 
of iodoacetyl-DIO solution and the mixture was incubated overnight at room temperature. The 417 
purchased peptide, C49H84N18O14S1, had a molecular weight of 1181.37 Da and an isoelectric point of 418 
pH 9.84. MiniPEG1 (8-amino-3,6-dioxaoctanoic acid) spacer was inserted to distance the peptide 419 
from the surface of the nanoparticle to allow for proper tertiary folded structure and allow better 420 
VCAM binding. Unreacted peptide was removed by using a Sephadex G-25 column equilibrated 421 
with 0.025M citrate buffer pH 6.5 at 4°C. The purified solution was lyophilized to give the final 422 
product that is the DIO nanoparticle with two ligands (DOTA and VCAM-1 targeting peptide) on 423 
the surface (VDIO-DOTA). 424 
5.2.4 Copper-64 labeled VDIO-DOTA  425 
Copper-64 was employed due to its relatively long half-life (12.7 h)[30] and comparatively 426 
stable coordination with multidentate macrocyclic compounds such as DOTA (log KML =  22.3).[31] 427 
VDIO-DOTA (25 mg) was dissolved in 150 µL of 0.2 M pH 5.5 sodium acetate-acetic acid buffer. 428 
Copper-64 (~ 2.5 mCi) was added to the vial and the mixture was vortexed for 5 seconds to obtain a 429 
uniform solution. The solution was incubated at 55-60 °C for 45 minutes. EDTA aqueous solution 430 
(16 µL, 100 mM) was added to the vial and vortexed for 5 seconds to get the solution uniform; then 431 
solution was incubated at 55-60 °C for 15 minutes. The crude product was purified by centrifuge 432 
filtration with 10K Da nanosep filtration tube (Millipore Inc., Billerica, MA, 30 min @14,000 rpm) 433 
and washed 3 times with pH 5.5 sodium acetate-acetic acid buffer. Each time the washing was 434 
removed by centrifuge filtration with a 10-kDa Nanosep filtration tube (10 min at 14,000 rpm). After 435 
three washings the filtration tube was turned over and inserted into a new vial, and the 436 
nanoparticles, VDIO-64Cu-DOTA, were collected by centrifuge (2 min @ 1,000 rpm). The radioactive 437 
nanoparticles were diluted to 650 µL with saline (0.9%) and radioactivity of the solution was 438 
measured with a Fluke Biomedical Dose calibrator (34- 162 CAL/RAD MARK IV, Cleveland, OH). 439 
The radiolabeling yield (%) for the NP, percent incorporation of radioisotope, was determined by 440 
dividing the radioactivity of the collected NP by the total activity applied to the column and 441 
multiplying by 100. For injection to animals VDIO-64Cu-DOTA (~ 15 µL) was passed through a 442 
sterile 0.22-micron filter before use. 443 
5.2.5 Characterization of VDIO-DOTA nanoparticles         444 
  
The iron concentration (mg) per unit mass of nanoparticles in DIO or VDIO-DOTA was 445 
measured with a Varian AA 220FS atomic absorption (AA) spectrophotometer using an 446 
air/acetylene flame. The iron-oxide core size of the VDIO-DOTA was measured by Transmission 447 
Electron Microscopy (TEM) on a Philips CM-12, operating at 80 kV and equipped with a 448 
GatanMegascan 795 digital camera. The core size was found by averaging the measurements of 500 449 
particles after drying a dilute drop of VDIO-DOTA particles over a lamp on a copper grid. The 450 
average hydrodynamic particle size (mean volume diameter) and distribution was measured using 451 
Dynamic Light Scattering (DLS) with a Nanotrac 150 particle size analyzer (Microtrac, Inc., 452 
Montgomeryville, PA) and geometric eight-root regression, with no residuals, was used to fit the 453 
data. The nano-range option was selected and a scan time of 90 seconds was used.  454 
Transverse relaxation times (T2) of the VDIO-DOTA particles were measured at 60 MHz (1.4 T) 455 
and 37 °C on a BrukerMinispec mq60. The relaxivity was given as the slope of the straight line 456 
plotted as the function of 1/T2 vs iron concentration. DIO and VDIO-DOTA were diluted in pH 7.0 457 
deionized water to give five aqueous solutions (300 µL each): 10.5, 5.25, 2.625, 1.313, and 0.656 mg 458 
Fe/L, respectively. Iron concentrations in each dilution were determined using Atomic Absorption 459 
Spectroscopy. T2 values were measured using a Carr-Purcell-Meiboom-Gill (CPMG) sequence with 460 
τ = 1 ms, and 200 data points. Each solution was incubated at 37°C for 5 minutes before 461 
measurement. 462 
5.3 Cytotoxicity 463 
Cytotoxicity of VDIO-DOTA was evaluated on HepG2 liver cells using C12 – Resazurin 464 
viability assays. HepG2 liver cells were cultured and maintained in Minimum Essential Medium 465 
containing 10% FBS, 200 U/mL penicillin, 200 µg/mL streptomycin, 1 mM sodium pyruvate, and 1 466 
mM nonessential amino acids at 37oC in a humidified 5% CO2 atmosphere. Cells were plated in 467 
96-well dishes at a concentration of 1 x 104 cells per well and incubated overnight (5% CO2, 37oC). 468 
After overnight incubation, media was replaced with fresh media containing VDIO-DOTA 469 
nanoparticles of varying concentration (0, 0.04, 0.2, 1, 4 and 10mM iron). Each concentration was 470 
performed in triplicate for statistical relevance. Cells were also treated with DIO nanoparticles 471 
under the same conditions as control. Cells were plated in three 96-well plates for measurements at 472 
time points of 4h, 24h and 48h. At each time point, nanoparticle solutions were removed and cells 473 
were washed with 1X PBS for three times. Then fresh media containing C12 – Resazurin (5µM) was 474 
added to each well of cells. After 15min of incubation, fluorescence was measured using a Safire 475 
monochromator microplate reader (Tecan Austria G.M.B.H., Austria) with excitation of 563nm and 476 
emission of 587nm.    477 
5.4 Iron staining 478 
Slides from the inflamed carotid were stained to evaluated for iron within the plaques using 479 
Prussian Blue Solution[32], a 1:1 mixture of 3% hydrochloride acid solution and 3% potassium 480 
ferrocyanide solution, to detect ferric ion (Fe3+) in the tissue. Any ferric ion present in the tissue 481 
reacted with the ferrocyanide and results in the formation of the bright blue pigment, Prussian blue, 482 
or ferric ferrocyanide. First, slides were deparaffinized by toluene and rehydrated through changes 483 
of ethanol with decreasing concentrations (100%, 95% and 75%). After rinsing, slides were placed in 484 
Prussian blue solution for 30 min followed by a rinsing step to remove excess staining. Then 485 
Nuclear Fast Red Staining was used to counterstain other tissue (pink) for 10 min. After 486 
dehydration with alcohol and clearing with toluene, tissue sections were placed under coverslips on 487 
slides with mounting media. 488 
5.5 Immunohistochemistry (IHC) 489 
The tissue sections were stained for inflammatory marker VCAM-1. The deparaffinization and 490 
dehydration process were the same as that of iron staining. Antigen retrieval was performed to 491 
unmask binding sites of the primary antibodies. Heat Induced Epitope Retrieval (HIER) was 492 
  
performed using a Decloaking Chamber. 500 ml of deionized water was added into the chamber. A 493 
plastic staining jar with tissue slides immersed in Antigen Retrieval Solution (Sigma 10X Tris-HCl 494 
buffer, pH10, product #T6455) was placed in the Decloaker chamber. The Decloaker was programed 495 
for 30 seconds at 125 °C followed by 10 seconds at 85 °C at 22.5 psi. After the heating process was 496 
done, the staining jar was removed from the Decloaker and cooled for 15 minutes followed by TBST 497 
rinse (Fisher 20X Tris buffered saline with Tween-20 used as 1X diluted solution). Then endogenous 498 
peroxidase block was performed by using 3% H2O2 in water to cancel the interference of peroxidase 499 
in the final step.[33] Protein block buffer (Dako Protein Block) was used to treat the tissue slides to 500 
mask the non-specific binding sites. Samples were labeled using an indirect method. Anti-VCAM-1 501 
antibody (Rabbit monoclonal [EPR5047] to VCAM-1, Abcam Inc., MA) was used as primary 502 
antibody to detect the VCAM-1 expression. Ready-to-use polymers carrying horseradish peroxidase 503 
(Dako North America, Inc., Carpinteria, CA) were then used as the secondary antibody. In the final 504 
staining step, peroxidase on the polymers reacted with hydrogen peroxide to reduce the DAB 505 
(3,3‘-Diaminobenzidine) substrate and generate a brown product in regions of VCAM-1 expression. 506 
Slides were examined under microscope.  507 
5.6 Animal Studies 508 
5.6.1 Animal model 509 
All animal studies were performed under protocols approved by the Animal Care and Use 510 
Committee of the University of California, Davis and the California Institute of Technology. Female 511 
C57BL/6 ApoE-/- (10 weeks old, Jax West Laboratories, West Sacramento, CA) mice were used for 512 
the experiments as described in previous studies.[14] Eight days prior to imaging, the left carotid 513 
artery of each mouse was ligated. Eight days was chosen because prior studies showed that 514 
VCAM-1 expression peaks between 7 and 10 days post-ligation in ApoE-/- mice.[34] At this stage 515 
pronounced plaques have not yet formed, but inflammation is evident. To perform the ligation a 516 
medial incision was made between the mandible and clavicle, exposing the glands and vessels of 517 
the neck. The carotid artery was singled out from the surrounding tissue, while protecting and 518 
excluding the parallel-running vagus nerve. A 6/0 silk suture was threaded under the dorsal side of 519 
the carotid artery and was tied off to cause injury to the site. The procedure was concluded with 520 
five to six interrupted 4/0 Ethicon (Ethicon Inc) suture to re-approximate the skin of the original 521 
ventral incision. The mice were monitored twice a day for approximately four days to check for 522 
irritation and to administer analgesics when appropriate. Subsequent to ligation, mice were placed 523 
on a high fat diet for seven days. (TD 88137, Harlan Laboratories Inc, Madison, WI).  524 
5.6.2 In vivo MRI-only studies 525 
MRI experiments were performed to determine the optimal injection dosages for the NPs prior 526 
to radiolabeling. Prior to NP injection, a pre-scan was taken as baseline. Then VDIO at dosages of 6 527 
mg Fe/kg body mass, 30 mg Fe/kg and 60 mg Fe/kg, were injected intravenously via the tail vein 528 
catheter (N = 4 per concentration). Images were acquired at 4 and 24 hours post-injection.  529 
All images were acquired on a 7T (Bruker Biospec) small animal scanner using a home built 530 
quadrature RF volume coil (Cleveland, OH). For all time points, the animal was anesthetized with a 531 
1.5% isoflurane: air mixture and kept at 35–37 °C with warm air flowing through the bore while the 532 
respiration was monitored (MP150, Biopac, Goleta, CA). After localizing the region of interest (ROI) 533 
around the neck using a RARE spin echo sequence (TR/TE = 4000/22 ms, matrix size = 128 × 128, 534 
FOV = 35.35 × 35.35 mm2, slice thickness = 0.754 mm), the common carotid arteries were located 535 
with a time-of-flight angiography sequence with venous saturation (FL2D_ANGIO method, 536 
Paravision 4.0: TR/TE = 13.7/3.5 ms, matrix size = 150 × 100; zero-filled to 256 × 100, FOV = 30 × 20 537 
mm2, slice thickness = 0.754 mm). A T2* weighted multiple-gradient echo sequence was then utilized 538 
to visualize the uptake of nanoparticles (TR/TE = 718/3, 7, 11, 15, 19, 23 ms, F.A. = 25°, matrix size = 539 
175 × 100; zero-filled to 234 × 133, FOV = 35 × 20 mm2, slice thickness = 0.754 mm) at the region of 540 
the common carotid arteries. 541 
  
5.6.3 In vivo PET/MRI imaging  542 
Studies were performed using an integrated small animal PET/MRI system, consisting of a 543 
first-generation MR-compatible PET insert (constructed by Simon Cherry et. al at UC Davis) that is 544 
fitted within a 7T small animal MRI scanner. [16, 17] This enabled simultaneous PET/MRI images to 545 
be acquired. 546 
Mice (N = 4) were surgically prepared as described above. Pre-scans were obtained with MRI 547 
as baseline. Next, mice were injected intravenously via the tail vein with 30 mg Fe/kg 548 
VDIO-64Cu-DOTA (~700uCi per mouse, 92% radiation yield) followed by a 150 µL of saline flush. 549 
The activity of the injected dose was confirmed by measuring the difference in radioactivity 550 
contained in the syringe before and after injection on a dose calibrator. Imaging was subsequently 551 
performed at 4 and 24 hours post-injection. MRI images were acquired identically to the MRI-only 552 
studies. PET images were acquired with scan duration of 600 seconds at the 4 hour time point and 553 
300 seconds at the 24 hour time point. Images were reconstructed and co-registered to the MRI 554 
dataset as previously described.[17, 35] 555 
To compare the focal NP uptake between time points, dosage and subjects, we calculated a 556 
contrast ratio (CR) metric as previously described.[36] This normalizes particle uptake at the 557 
ligation site between subjects and factors out the signal contribution due to blood borne particles by 558 
comparison with the contralateral control. 559 
Briefly, CR is defined as: 560 
𝑪𝑹 =	%% &
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 561 
Where Iligated is the mean intensity of the ROI drawn around the ligated carotid artery, Icontrol is the 562 
mean intensity of the ROI drawn around the contra-lateral carotid. Ibackground is the mean intensity of 563 
the ROI drawn in the spinal cord at the same image slice as the other ROIs and i is either 4 or 24 564 
hours post-injection time points. ROIs were drawn manually at slice levels approximately located at 565 
the common carotid arteries. These were matched between time points. Angiography images were 566 
used to guide ROI delineation around the carotid arteries. Because previous reports noted that the 567 
carotid vessels along with the wall are ~1 mm in diameter,[36] all arterial ROIs had diameters of 1.5 568 
mm. 569 
Representative region of interests used for CR calculation are indicated in Figure 3. Values 570 
greater than 1 indicate localization at the ligation site. The T2* weighted image sets at TE = 11 ms 571 
were used. All images were analyzed using ImageJ.  572 
5.6.4 Visualization of image volumes 573 
We developed a hardware accelerated volume rendering system with enhanced rendering 574 
quality to provide better visualization of the PET and MRI signal at the site of the inflamed arteries. 575 
To provide anatomical context, we superimpose a cross section of the data. Illustrative 576 
rendering[37] is applied to this cross section for relative spatial position of the target vessel. The 577 
vessel ROIs were manually segmented from the MRI images to identify the vessel walls. A 578 
pre-integrated transfer function[38] was used to visualize the thin layer of vessel wall as a smooth 579 
and continuous surface. To highlight the NP uptake on the surface of the arteries, we used a color 580 
map to sort the surface MR signal ranging from red (low MR signal), through blue (medium) to 581 
light pink (high MR). 582 
5.7 Histology 583 
After the in vivo animal study, organs known to be involved in disease or clearance, i.e. hearts, 584 
carotid arteries, kidneys, spleens and livers, were collected and used for histology. The tissue was 585 
  
fixed in 4% formaldehyde, and then dehydrated by passing tissue through increasing 586 
concentrations of ethanol (75%, 95% and 100%). Then the tissue was placed in warm paraffin wax, 587 
and the melted wax filled the spaces that used to contain water. After cooling, the tissue hardened 588 
into a paraffin block from which 5-micron tissue slices were sectioned and mounted on glass slides. 589 
The tissue sections were stained for iron and VCAM-1 as detailed in Supplemental Information.   590 
Supplementary Materials: N/A 591 
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